# mFLUSIVA

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mflusiva
Canonical HTML page: https://getbiobrief.com/entity/mflusiva

## Recent coverage (1 stories)

### Moderna’s mFLUSIVA mRNA Flu Vaccine Wins FDA Nod: 40,000-Patient Trial Suggests Superiority
2026-08-06 20:24:09 · Sentiment: Positive · Impact: 6/10 · Sources: 3

The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Full story: https://getbiobrief.com/story/moderna-mrna-flu-vaccine-approval-fda

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.